• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by VolitionRX Limited

    11/14/24 3:40:04 PM ET
    $VNRX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $VNRX alert in real time by email
    SC 13G 1 armistice-vnrx093024.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*



    VOLITIONRX LTD

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

    928661107

    (CUSIP Number)

     

     

    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  928661107
     SCHEDULE 13G
    Page 2 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Armistice Capital, LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    9,223,380
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    9,223,380
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    9,223,380
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.99%
    12
    TYPE OF REPORTING PERSON
     
    IA, OO

     


     

    CUSIP No.  928661107
     SCHEDULE 13G
    Page 3 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Steven Boyd
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States of America
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    9,223,380
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    9,223,380
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    9,223,380
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.99%
    12
    TYPE OF REPORTING PERSON
     
    IN, HC

     


     

     

    CUSIP No. 928661107
     SCHEDULE 13G
    Page 4 of 8 Pages

     

    Item 1.(a) Name of Issuer

    VOLITIONRX LTD

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    1489 West Warm Springs Road, Suite 110

    Henderson, Nevada 89014

    Item 2.(a) Names of Person Filing:

    Armistice Capital, LLC

    Steven Boyd

    Collectively, the "Reporting Persons"

      

    Item 2.(b) Address of Principal Business Office:

     

    Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

     

    Steven Boyd

    c/o Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

      

    Item 2.(c) Citizenship:

     

    Armistice Capital, LLC - Delaware

    Steven Boyd - United States of America

      

    Item 2.(d) Title of Class of Securities

     

    Common Stock, par value $0.001 per share (“Shares”)

     

    Item 2.(e) CUSIP No.:

    928661107

     

    CUSIP No.  928661107
     SCHEDULE 13G
    Page 5 of 8 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) x A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

    CUSIP No. 928661107
     SCHEDULE 13G
    Page 6 of 8 Pages

     

     

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount beneficially owned as of September 30, 2024:

    Armistice Capital, LLC - 9,223,380

    Steven Boyd - 9,223,380  

    (b) Percent of Class as of September 30, 2024:

    Armistice Capital, LLC - 9.99%

    Steven Boyd - 9.99% 

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote

    Armistice Capital, LLC - 0

    Steven Boyd - 0 

    (ii) Shared power to vote or to direct the vote

    Armistice Capital, LLC - 9,223,380

    Steven Boyd - 9,223,380 

    (iii) Sole power to dispose or to direct the disposition of

    Armistice Capital, LLC - 0

    Steven Boyd - 0 

    (iv) Shared power to dispose or to direct the disposition of

    Armistice Capital, LLC - 9,223,380

    Steven Boyd - 9,223,380

    The percentage of Shares reported to be beneficially owned by the Reporting Persons are based on information from the Issuer.

    Armistice Capital, LLC (“Armistice Capital”) is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

     

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 928661107
     SCHEDULE 13G
    Page 7 of 8 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

     

     

     

    Armistice Capital, LLC

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

    Managing Member

           

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

           

     

     
    CUSIP No. 928661107
     SCHEDULE 13G
    Page 8 of 8 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: November 14, 2024

     

     

    Armistice Capital, LLC

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

    Managing Member

           
     

     
      By:  /s/ Steven Boyd
       

    Steven Boyd

           
    Get the next $VNRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VNRX

    DatePrice TargetRatingAnalyst
    4/8/2025$2.50Buy
    H.C. Wainwright
    2/1/2023Buy → Hold
    The Benchmark Company
    2/17/2022$8.00 → $7.00Overweight
    Cantor Fitzgerald
    11/16/2021$10.00 → $9.00Buy
    Aegis Capital
    More analyst ratings

    $VNRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Innes Guy Archibald bought $10,772 worth of shares (20,000 units at $0.54), increasing direct ownership by 2% to 888,689 units (SEC Form 4)

      4 - VOLITIONRX LTD (0000093314) (Issuer)

      6/4/25 7:55:21 AM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chief Scientific Officer Micallef Jacob Vincent bought $21,500 worth of shares (50,000 units at $0.43), increasing direct ownership by 13% to 426,033 units (SEC Form 4)

      4 - VOLITIONRX LTD (0000093314) (Issuer)

      5/19/25 1:23:05 PM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • President and CEO Reynolds Cameron John bought $8,730 worth of shares (20,000 units at $0.44), increasing direct ownership by 0.87% to 2,319,222 units (SEC Form 4)

      4 - VOLITIONRX LTD (0000093314) (Issuer)

      5/19/25 12:43:56 PM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $VNRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on VolitionRx with a new price target

      H.C. Wainwright initiated coverage of VolitionRx with a rating of Buy and set a new price target of $2.50

      4/8/25 8:02:28 AM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • VolitionRx downgraded by The Benchmark Company

      The Benchmark Company downgraded VolitionRx from Buy to Hold

      2/1/23 7:40:33 AM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Cantor Fitzgerald resumed coverage on VolitionRx with a new price target

      Cantor Fitzgerald resumed coverage of VolitionRx with a rating of Overweight and set a new price target of $7.00 from $8.00 previously

      2/17/22 9:10:02 AM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $VNRX
    Financials

    Live finance-specific insights

    See more
    • VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update

      Conference call to discuss financial and operational results scheduled for Friday, May 16 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev., May 15, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the first quarter ended March 31, 2025.  Volition management will host a conference call tomorrow, May 16 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below. Cameron Reynolds, President and Group Chief Executive Officer, said: "2025 is a pivotal year for Volition as we focus on commercializing our ground breaking Nu.Q® platform in the hum

      5/15/25 5:37:00 PM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update

      Conference call to take place on Friday, May 16 at 8:30 a.m. U.S Eastern Time Henderson, Nev., May 12, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announces that it will host a conference call on Friday, May 16 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the first quarter of 2025 and to provide a business update. Details of this event can be found below. Event:   VolitionRx Limited First Quarter 2025 Earnings and Business Update Conference CallDate:     Friday, May 16, 2025 Time:    8:30 a.m. U.S. Eastern Time/2.30 p.m. Central European Time U.S. & Canada Dial-in: 1-877-407-9716 (toll free)U.K. Dial-in: 0 800 756 3429 (toll fr

      5/12/25 8:30:00 AM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update

      Conference call to take place on Monday, March 31 at 4:30 p.m. U.S Eastern Time HENDERSON, Nev., March 25, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition") today announces that it will host a conference call on Monday, March 31 at 4.30 p.m. U.S. Eastern Time to discuss its financial and operating results for the fourth quarter and full fiscal year 2024, in addition to providing a business update. Details of this event can be found below. Event: VolitionRx Limited Full Fiscal Year 2024 Earnings and Business Update Conference CallDate: Monday, March 31, 2025Time: 4:30 p.m. U.S. Eastern Time U.S. & Canada Dial-in: 1-877-407-9716 (toll free)U.K. Dial-in: 0 800 756 3429 (toll fre

      3/25/25 9:30:00 AM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $VNRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties

      HENDERSON, Nevada, June 4, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces two oral presentations featuring its Nu.Q® Vet Cancer Test at the Asian Meeting of Animal Medicine Specialties (AMAMS 2025), a premier event bringing together leading veterinary professionals and experts from across Asia. The two presentations feature results from two clinical studies conducted by Dr Masahiko Sato, DVM, PhD, DACVIM (SAIM), DAiCVIM (IM) in conjunction with FujiFilm Vet Systems. Dr Sato, a key opinion leader is Chief of Internal Medicine Service at the Veterinary Specialists Emergency Center, one of the largest referral hospitals in

      6/4/25 9:00:00 PM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats

      Clinical Paper Published in BMC Veterinary Research HENDERSON, Nev., May 19, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces the publication of "Evaluation of plasma nucleosome concentrations and the effect of pre-analytical variables in healthy cats" in BMC Veterinary Research. This is the first study to report the detection of nucleosomes in cats: previously nucleosome levels have been shown to increase in dogs and humans in certain disease states, including cancer. Frederic Wuilque, Vice President, Global Products, said: "This is an essential step in the development of Nu.Q® products for cats, our third species. This

      5/19/25 8:30:00 AM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update

      Conference call to discuss financial and operational results scheduled for Friday, May 16 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev., May 15, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the first quarter ended March 31, 2025.  Volition management will host a conference call tomorrow, May 16 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below. Cameron Reynolds, President and Group Chief Executive Officer, said: "2025 is a pivotal year for Volition as we focus on commercializing our ground breaking Nu.Q® platform in the hum

      5/15/25 5:37:00 PM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $VNRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by VolitionRX Limited

      SC 13G - VOLITIONRX LTD (0000093314) (Subject)

      11/14/24 4:05:14 PM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G filed by VolitionRX Limited

      SC 13G - VOLITIONRX LTD (0000093314) (Subject)

      11/14/24 3:40:04 PM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by VolitionRX Limited (Amendment)

      SC 13G/A - VOLITIONRX LTD (0000093314) (Subject)

      2/14/24 4:05:45 PM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $VNRX
    SEC Filings

    See more

    $VNRX
    Leadership Updates

    Live Leadership Updates

    See more
    • SEC Form D filed by VolitionRX Limited

      D - VOLITIONRX LTD (0000093314) (Filer)

      5/30/25 4:13:34 PM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 10-Q filed by VolitionRX Limited

      10-Q - VOLITIONRX LTD (0000093314) (Filer)

      5/15/25 5:27:40 PM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • VolitionRX Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - VOLITIONRX LTD (0000093314) (Filer)

      5/15/25 5:26:48 PM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Volition Issues Business Review 2024

      HENDERSON, Nev., Jan. 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, has issued a Business Review of 2024, outlining its key highlights from the past year. Volition's major achievements in 2024 include: Expanded access to the Nu.Q® Vet Cancer Test – now available for purchase in 20 countries worldwide.Sold over 110,000 Nu.Q® Vet Cancer Tests in the first three quarters 2024.Hosted Satellite Symposium at European Society of Intensive Care Medicine 2024 showcasing Nu.Q® NETs clinical utility in over 3,000 intensive care sepsis patients.Continued to strengthen our strategic patent portfolio.Made significant progress a

      1/8/25 8:30:00 AM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Volition Appoints Timothy I. Still as Chairman

      HENDERSON, Nev., Nov. 6, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, has appointed Timothy Still as Chairman of its board of directors, effective November 06, 2024. Mr. Still is currently Chairman and CEO of TSTILL Enterprises LLC, and an Operating Partner with REVIVAL Healthcare. An accomplished executive with a career spanning over 35 years in medical diagnostics, devices and digital health, his background includes extensive experience in designing and implementing highly focused commercial and business development

      11/6/24 4:10:00 PM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Volition Appoints Dr. Ethel Rubin as an Independent Director

      HENDERSON, Nev., Sept. 30, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, has appointed Dr. Ethel Rubin to its board of directors, as an independent director, effective September 30, 2024. Dr. Rubin has also been appointed as a member of the Audit Committee and the Compensation Committee. Dr. Rubin has over 20 years' experience within the life sciences sector, leading healthcare innovation and commercialization strategies for a wide range of organizations – from early-stage operations to large global corporate businesses

      9/30/24 4:10:00 PM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $VNRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Innes Guy Archibald bought $10,772 worth of shares (20,000 units at $0.54), increasing direct ownership by 2% to 888,689 units (SEC Form 4)

      4 - VOLITIONRX LTD (0000093314) (Issuer)

      6/4/25 7:55:21 AM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • CEO - Singapore Volition Kway Jasmine was granted 8,327 shares, increasing direct ownership by 5% to 191,107 units (SEC Form 4)

      4 - VOLITIONRX LTD (0000093314) (Issuer)

      6/3/25 4:07:04 PM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Director Nguyen Kim was granted 11,983 shares, increasing direct ownership by 14% to 98,392 units (SEC Form 4)

      4 - VOLITIONRX LTD (0000093314) (Issuer)

      6/3/25 4:06:49 PM ET
      $VNRX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care